Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 6/20 | 1.00 |
| ▸ | MAOB | P27338 | 3/20 | 0.44 |
| ▸ | MAOA | P21397 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 5/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | CRHBP | P24387 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1655432 | 0.92 | S1PR1 (0.86) | S1PR1MAOBMAOATP53MAPT | |
| SCHEMBL1655409 | 0.85 | S1PR1 (0.74) | S1PR1MAOBMAOATP53MAPT | |
| SCHEMBL1654649 | 0.83 | S1PR1 (0.76) | S1PR1MAOBMAOATP53MAPT | |
| SCHEMBL1654612 | 0.81 | S1PR1 (0.79) | S1PR1MAOBMAOACNR2MEN1 | |
| SCHEMBL1653737 | 0.81 | S1PR1 (0.76) | S1PR1MAOBMAOATP53MAPT | |
| SCHEMBL1655442 | 0.81 | S1PR1 (0.77) | S1PR1MAOBMAOATP53MAPT | |
| SCHEMBL3888542 | 0.80 | S1PR1 (0.77) | S1PR1MAOBMAOATP53MAPT | |
| SCHEMBL1654596 | 0.79 | S1PR1 (1.00) | S1PR1MAOBMAOACNR2RAB9A | |
| SCHEMBL1654349 | 0.79 | S1PR1 (0.77) | S1PR1MAOBMAOATP53MAPT | |
| SCHEMBL1653783 | 0.79 | S1PR1 (0.81) | S1PR1MAOBMAOACNR2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9572792-B2 | Coumarin compounds as receptor modulators with therapeutic utility | ALLERGAN, INC. (US) | 2017-02-21 | — | — | US | claimed |
| US-20150265573-A1 | COUMARIN COMPOUNDS AS RECEPTOR MODULATORS WITH THERAPEUTIC UTILITY | ALLERGAN, INC. | 2015-09-24 | — | — | US | claimed |
| US-9073888-B2 | Coumarin compounds as receptor modulators with therapeutic utility | ALLERGAN, INC. (US) | 2015-07-07 | — | — | US | claimed |
| EP-2491023-B1 | COUMARIN COMPOUNDS AS RECEPTOR MODULATORS WITH THERAPEUTIC UTILITY | ALLERGAN INC (US) | 2014-12-31 | — | — | EP | claimed |
| US-20120328661-A1 | COUMARIN COMPOUNDS AS RECEPTOR MODULATORS WITH THERAPEUTIC UTILITY | ALLERGAN, INC. (US) | 2012-12-27 | — | — | US | claimed |
| EP-2491023-A2 | COUMARIN COMPOUNDS AS RECEPTOR MODULATORS WITH THERAPEUTIC UTILITY | Allergan, Inc. (US) | 2012-08-29 | — | — | EP | claimed |
| WO-2011050054-A2 | COUMARIN COMPOUNDS AS RECEPTOR MODULATORS WITH THERAPEUTIC UTILITY | ALLERGAN, INC. (US) | 2011-04-28 | — | — | WO | claimed |
| US-9572792-B2 | Coumarin compounds as receptor modulators with therapeutic utility | ALLERGAN, INC. (US) | 2017-02-21 | — | — | US | disclosed |
| US-20150265573-A1 | COUMARIN COMPOUNDS AS RECEPTOR MODULATORS WITH THERAPEUTIC UTILITY | ALLERGAN, INC. | 2015-09-24 | — | — | US | disclosed |
| US-9073888-B2 | Coumarin compounds as receptor modulators with therapeutic utility | ALLERGAN, INC. (US) | 2015-07-07 | — | — | US | disclosed |
| EP-2491023-B1 | COUMARIN COMPOUNDS AS RECEPTOR MODULATORS WITH THERAPEUTIC UTILITY | ALLERGAN INC (US) | 2014-12-31 | — | — | EP | disclosed |
| US-20120328661-A1 | COUMARIN COMPOUNDS AS RECEPTOR MODULATORS WITH THERAPEUTIC UTILITY | ALLERGAN, INC. (US) | 2012-12-27 | — | — | US | disclosed |
| EP-2491023-A2 | COUMARIN COMPOUNDS AS RECEPTOR MODULATORS WITH THERAPEUTIC UTILITY | Allergan, Inc. (US) | 2012-08-29 | — | — | EP | disclosed |
| WO-2011050054-A2 | COUMARIN COMPOUNDS AS RECEPTOR MODULATORS WITH THERAPEUTIC UTILITY | ALLERGAN, INC. (US) | 2011-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150265573-A1 | COUMARIN COMPOUNDS AS RECEPTOR MODULATORS WITH THERAPEUTIC UTILITY | S1PR3, S1PR1, S1PR2 | S1PR1 2/4885MAOB 3447/4885MAOA 3579/4885 |
| US-20120328661-A1 | COUMARIN COMPOUNDS AS RECEPTOR MODULATORS WITH THERAPEUTIC UTILITY | S1PR3, S1PR1, S1PR2 | S1PR1 2/4885MAOB 3447/4885MAOA 3579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.